Results of a nationwide survey in Japan on transplantation in patients with pre-formed anti-donor specific antibody against HLA antigen, and on the use of rituximab in this transplantation

DOI
  • NAKAGAWA Ken
    Department of Urology, Ichikawa General Hospital Tokyo Dental College
  • AKAMATSU Nobuhisa
    Artificial Organ and Transplantation Surgery Division, Department of Surgery, The University of Tokyo Graduate School of Medicine
  • ITO Taihei
    Department of Transplantation Regenerative Medicine, Fujita Health University Graduate School of Medicine
  • UENO Takehisa
    Department of Pediatric Surgery, Osaka University Graduate School of Medicine
  • OKUMI Masayoshi
    Department of Urology, Tokyo Women’s Medical University
  • SAKAMOTO Seisuke
    Organ Transplantation Center, National Center for Child Health and Development
  • CHEN-YOSHIKAWA Toyofumi F.
    Department of Thoracic Surgery, Kyoto University Graduate School of Medicine Department of Thoracic Surgery, Nagoya University Graduate School of Medicine
  • NAWATA Kan
    Department of Cardiac Surgery, The University of Tokyo Hospital Department of Cardiovascular Surgery, St Marianna University School of Medicine
  • FUKUSHIMA Norihide
    Department of Transplant Medicine, National Cerebral and Cardiovascular Center
  • SATOH Shigeru
    Center for Kidney Disease and Transplantation, Akita University Hospital
  • EGAWA Hiroto
    Department of Gastroenterological Surgery, Institute of Gastroenterology, Tokyo Women's Medical University

Bibliographic Information

Other Title
  • 抗ドナー特異的抗体陽性臓器移植の実態とrituximabの使用に関する全国使用実態調査結果

Search this article

Description

<p>A retrospective survey was conducted to assess the status of organ transplantation in patients with pre-formed donor-specific anti-HLA antibodies and the implementation of desensitization with rituximab in Japan. We obtained the data from 227 institutions for procedures performed between 2013 and 2016 for kidney transplantation and between 2001 and 2016 for transplantation of other organs, including the liver, pancreas, heart, lung, and intestine.</p><p>Results showed pre-formed donor-specific antibodies (DSA) in recipients of 529 transplanted kidneys; rituximab was used in 462 of those transplantations. Rituximab was used in 48 of 135 liver transplantations in recipients with pre-formed DSA and in 1 of 1 small intestine transplantation involving pre-formed DSA. Such DSA was also reported in 5 heart transplants and 4 lung transplants. However, rituximab was not used for desensitization in any of those procedures.</p><p>We also report on detection and assay of anti-HLA antibodies and DSA, criteria for transplantation, dosage of rituximab, and concomitant immunosuppressive drugs used at the institutions.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top